Drug retail meager survival 39 chain by China Resources Medicine "abandoned"

In recent years the mismanagement of the chain of pharmacy well-known brands Shenzhen 39 pharmaceutical Chain Co., Ltd. (hereinafter referred to as 39 chain), after several internal turnover, eventually can not get rid of two major shareholders completely abandoned fate. February 10, the listing information of Shanghai United Property Exchange shows that Wuxi Hui Run Pharmaceutical Co., Ltd. and China Resources Pharmaceutical Investment Co., Ltd., to sell the total price of 8.92 million yuan of its 39 chain 93.6047%, 6.3953%, a total of 100% of the equity. From the listing information, Wuxi Huiyun the transfer of 39 of the franchise is also China Resources Corporation, which should be associated with CRC. Industry analysts said that the fixed cost of increasing year by year, the growth of pharmaceutical retail industry slowdown in the environment, many small and medium-sized or single retail pharmacies have to face the reality of increasingly difficult profits. Or because of the difficult earnings listed information shows that in the first half of 2013, 39 chain operating income, net profit of 10.48 million yuan, 5.7934 million yuan, net assets of 7.9189 million yuan. Walkson (Beijing) International Assets Assessment Co., Ltd. for its assessment of the first half of last year, the company valued at 8.91 million yuan, the proposed transfer price of 8.92 million yuan. 39 chain was founded in May 2000, the original Sanjiu group Chairman Zhao Xin first set up in the beginning of the national launch of "Million shop plan", hoping to borrow 39 chain to drive the development of pharmaceutical industry. Data show that the 39 chain after vigorous expansion, brilliant business in 15 provinces, more than 1000 stores, 2003 after-tax sales reached 615 million yuan. But this extensive business model soon blew the bubble, 39 chain did not bring the expected effect. According to previous announcement data, 2004 annual 39 chain business revenue for 824 million yuan, but net profit is-69.01 million yuan; 2005 years ago, September to achieve the main business income 630 million yuan, net profit of 29.48 million yuan. Because the parent company 39 Medicine Management appeared the problem, the capital chain breakage, the 39 chain also subsequently plunged into the management predicament. In July 2007, China Resources Medicine acquired the effective assets including 39 chains, and incorporated the huge assets of Sanjiu group into the China Resources medicine territory. However, the 39 chain in the China Resources Group Medicine, the business super system inside also changed hands. July 2011, China Resources Venture (00291,HK) under the Shenzhen Huarun Hall to 72.96 million yuan in the price of the acquisition of 39 chain of 152 chain pharmacies, 39 chain thus included in the China resources million supermarkets system, there is speculation in the industry to build OTC drug sales platform. Yesterday, the "Daily economic news" reporter call China resources million brand consulting, to the deadline, China resources million did not respond to the above 39 chain of strategic speculation, and did not answer the group why the sale of 39 chain. It is widely believed that poor performance, bleak prospects or the 39 chain become chicken ribs, the ultimate abandonment of the root cause. Public data show that the 39 chain in recent years performance is not clear: 2009 turnover of 269 million yuan, net profit of 5.736 million yuan2010 turnover of 319 million yuan, net profit of 5.13 million yuan. By 2012, 39 chain net profit was 4.9857 million yuan. The general slowdown in drug retailing in fact, after the last round of explosive growth, the whole drug retail industry growth is gradually slowing down. China Kang information data show that 2012, the drug market size of the entity pharmacies amounted to 179.8 billion yuan, retail pharmacies increased by 3.5%, of which the number of stores in the stores, a negative growth of pharmacies. The head of a large chain pharmacy in Guangdong told the Daily Economic news reporter that the decline of the drug retail industry is an indisputable fact, in the operating fixed cost of 5% to 10% per annum, drug profit decreasing situation, retail pharmacies are facing different degrees of impact, and some small and medium-sized chain pharmacies, single shop management more laborious. Some industry insiders have said that at present our country is about 1/3 of the drugstore loss, 1/3 of the pharmacy flat, only 1/3 of the drugstore profit. "Annual labor, rent and other management costs are not rising, the national Development and Reform Commission has also adjusted the price of drugs, some pharmacies do not go down the door." Coupled with the new version of "Drug Management Quality Management Standards Certification" (hereinafter referred to as GSP) standards such as strict policies and the impact of pharmaceutical manufacturers, the future of drug retailing will be less profit. "Even large chain pharmacies are starting to try a diversified platform, such as the Electronic Business platform and client file management," the source said. At the beginning of last year, the State administration of Food and Drug Administration issued a new revised GSP standard for the drug circulation industry, which is many, small and scattered. Until December 31, 2015, all pharmaceutical enterprises, regardless of the "drug business license" or "Drug management Quality Management Standard Certification Certificate" (commonly known as "Double certificate") whether the expiration, must meet the requirements of the new version of GSP. Since January 1, 2016, the new GSP requirements have not been met, shall not continue to engage in drug business activities. A veteran who has long been concerned about the field of medicine has disclosed to the daily economic news that a large number of pharmacies that do not reach the requirements will cease to operate by 2015 if strictly implemented according to the new GSP standards.